Thursday 16 April 2026

One To Watch

Cartesian Therapeutics

A clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases.

Company Overview

Want to Update your Company's Profile?


Latest Cartesian Therapeutics News

The week in pharma: action, reaction and insight – week to April 11
13 April 2025
Cell therapy scores year-long benefit in myasthenia gravis, heads to Phase III
9 April 2025
Moving into Phase III, Cartesian data show momentum
4 December 2024
FDA grants rare pediatric status for Cartesian’s Descartes-08
9 September 2024
More Cartesian Therapeutics news >


Today's issue

Yvonne McGrath named CSO at Enodia
Biotechnology
Yvonne McGrath named CSO at Enodia
15 April 2026
Biotechnology
Beeline Medicines debuts with BMS-derived pipeline
15 April 2026
Pharmaceutical
J&J beats estimates and raises forecast
15 April 2026
Pharmaceutical
Neffy approved as the first needle-free anaphylaxis treatment in Canada
15 April 2026
Pharmaceutical
FDA demands trial safety data on Foundayo after approval
15 April 2026
Pharmaceutical
Rubicon enters Indian CNS formulations market with buy of Arinna Lifesciences
15 April 2026
Biotechnology
Obsidian and Galera reveal reverse merger plan
15 April 2026




Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze